Clinical case: idelalisib-induced immunoglobulin flare. (4th July 2017)

• Record Type: Journal Article
• Authors: Novak, Jan; Havrda, Martin; Gaherova, Lubica; Spicka, Jan; Kozak, Tomas
• Is Part Of: Immunopharmacology and immunotoxicology. Volume 39:Number 4(2017:Aug.)
• Page Start: 251
• Page End: 252
• Publication Date: 2017-07-04
• Subjects: Idelalisib -- immunoglobulin flare -- chronic lymphocytic leukemia -- complication -- treatment; Immunopharmacology -- Periodicals; Immunotoxicology -- Periodicals; Antibody-toxin conjugates -- Periodicals; Immunology -- Periodicals; 615.37
• DOI: 10.1080/08923973.2017.1318912
• Languages: English
• ISSNs: 0892-3973

Abstract

Abstract: IgM flare is a transient, treatment-induced, increase of monoclonal IgM levels in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) patients. Until recently this phenomenon was observed in patients treated with Cladribine and Rituximab. Here we report a case of a heavily pretreated chronic lymphocytic leukemia patient with an atypically high immunoglobulin production who developed clinically significant immunoglobulin flare following Idelalisib treatment.